MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Operating Income 2011-2026 | EW
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.26 B | 1.38 B | 1.31 B | 1.5 B | 1.69 B | 898 M | 1.15 B | 748 M | 1.09 B | 751 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.69 B | 748 M | 1.18 B |
Quarterly Operating Income Edwards Lifesciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 307 M | 411 M | 395 M | - | 351 M | 366 M | 349 M | - | 366 M | 264 M | 388 M | - | 402 M | 460 M | 439 M | - | 390 M | 542 M | 384 M | - | 358 M | -170 M | 358 M | - | 294 M | 268 M | 274 M | - | 249 M | 252 M | 252 M | - | 214 M | 241 M | 298 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 542 M | -170 M | 322 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M |  USA |
 |
Delcath Systems
DCTH
|
660 K | $ 9.13 | -0.76 % | $ 327 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 9.38 | -1.78 % | $ 722 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.5 | 1.25 % | $ 173 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.35 | 1.89 % | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
26.1 M | $ 98.74 | -2.99 % | $ 1.26 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.35 | 0.74 % | $ 384 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
LENSAR
LNSR
|
-10.7 M | $ 5.52 | -1.08 % | $ 63.6 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.64 | -1.19 % | $ 1.14 B | USA |
 |
Medtronic PLC
MDT
|
5.96 B | $ 87.67 | -0.24 % | $ 113 B | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.45 | -0.85 % | $ 207 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.79 | -1.17 % | $ 467 M |  Curacao |
 |
Outset Medical
OM
|
-66.7 M | $ 3.52 | -0.28 % | $ 53.5 K | USA |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.6 | -10.61 % | $ 32.7 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.27 | -2.16 % | $ 3.54 M | USA |
 |
PAVmed
PAVM
|
-68.8 M | $ 8.94 | -3.87 % | $ 64.7 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 63.65 | 0.55 % | $ 3.47 B |  Britain |
 |
InspireMD
NSPR
|
-49.6 M | $ 1.73 | -2.26 % | $ 111 M |  Israel |
 |
Insulet Corporation
PODD
|
474 M | $ 218.11 | 0.98 % | $ 15.3 B | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.41 | 0.18 % | $ 1.54 B | USA |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.9 | -1.52 % | $ 166 M | USA |
 |
Penumbra
PEN
|
189 M | $ 336.42 | 0.04 % | $ 13.1 B | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.94 | -3.9 % | $ 582 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-27 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.68 | -2.2 % | $ 28.5 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 50.45 | -1.87 % | $ 1.48 B | USA |